糖尿病前期
医学
内科学
糖耐量受损
胰岛素抵抗
糖尿病
内分泌学
2型糖尿病
糖耐量试验
空腹血糖受损
血糖
作者
Muhammad Abdul‐Ghani,Mohamed Abu‐Farha,Tamam Abdul‐Ghani,Alberto Chavez-Velazquez,Auora Merovci,Ralph A. DeFronzo,Fahad Al-Ajmi,Michael P. Stern,Fahd Al‐Mulla
出处
期刊:Diabetes Care
[American Diabetes Association]
日期:2025-05-16
卷期号:48 (7): 1273-1279
被引量:2
摘要
OBJECTIVE To examine the ability of the 1-h plasma glucose (PG) concentration during the oral glucose tolerance test (OGTT) to predict the risk of progression to prediabetes in individuals with normal glucose tolerance (NGT). RESEARCH DESIGN AND METHODS A total of 1,557 participants from the San Antonio Heart Study who were free of type 2 diabetes at baseline, had a baseline OGTT, and had a repeat OGTT after 7.5 years of follow-up were evaluated. The ability of 1-h PG concentration to predict the development of prediabetes, based on American Diabetes Association criteria, was evaluated. RESULTS Approximately one-quarter of participants with NGT (24.7%) progressed to prediabetes at 7.5 years (22.5% with 1-h PG <155 mg/dL and 42.5% with 1-h PG >155 mg/dL). The 1-h PG was the strongest predictor of developing prediabetes, and a 1-h cut point of 120 mg/dL had 61% sensitivity and 67% specificity in identifying individuals with NGT at high risk of developing prediabetes. Participants with a 1-h PG of 120–155 mg/dL and who experienced a deterioration in glucose tolerance (progression to prediabetes) at follow-up were characterized by severe insulin resistance and metabolic abnormalities characteristic of the insulin resistance syndrome. Therefore, we suggest the term pre-prediabetes for this group to emphasize their high future risk of deteriorating glucose tolerance. CONCLUSIONS An increase in 1-h PG concentration precedes the development of prediabetes and identifies individuals with a 1-h PG of 120–155 mg/dL who are at increased risk of developing prediabetes. Therefore, we suggest the term pre-prediabetes for this group with an elevated risk of deteriorating glucose tolerance.
科研通智能强力驱动
Strongly Powered by AbleSci AI